(Q32083078)

English

Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

1 reference

Europe PubMed Central

Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Bishop JF

1

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Matthews JP

2

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Young GA

3

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Bradstock K

4

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Lowenthal RM

5

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

publication date

1 January 1998

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

3-4

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

315-327

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.3109%2F10428199809092687

21 January 2018

Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428199809092687

21 January 2018

Acute nonlymphoblastic leukemia: prognostic factors in adults with long-term follow-up.

1 reference

https://api.crossref.org/works/10.3109%2F10428199809092687

21 January 2018

High remission-induction rate in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.3109%2F10428199809092687

21 January 2018

Daunomycin, cytosine arabinoside and 6-thioguanine (DAT) vs vincristine, cytosine arabinoside and 6-thioguanine (VAT) in the induction treatment of acute nonlymphocytic leukemia: A randomized collaborative study

1 reference

https://api.crossref.org/works/10.3109%2F10428199809092687

21 January 2018

A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428199809092687

21 January 2018

Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival

1 reference

https://api.crossref.org/works/10.3109%2F10428199809092687

21 January 2018

Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial

1 reference

https://api.crossref.org/works/10.3109%2F10428199809092687

21 January 2018

4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428199809092687

21 January 2018

4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study.

1 reference

https://api.crossref.org/works/10.3109%2F10428199809092687

21 January 2018

Current status of treatment of acute leukemia in adults: an overview of the Memorial experience and review of literature

1 reference

https://api.crossref.org/works/10.3109%2F10428199809092687

21 January 2018

Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.3109%2F10428199809092687

21 January 2018

High-dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukaemia: a single centre study

1 reference

https://api.crossref.org/works/10.3109%2F10428199809092687

21 January 2018

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428199809092687

21 January 2018

Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.3109%2F10428199809092687

21 January 2018

The role of intensive remission induction and consolidation therapy in patients with acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.3109%2F10428199809092687

21 January 2018

Identifiers

10.3109/10428199809092687

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q32083078&oldid=1786019338"